Antioxidant hepatic lipid metabolism can be promoted by orally administered inorganic nanoparticles
Accumulation of inorganic nanoparticles in living organisms can cause an increase in cellular reactive oxygen species (ROS) in a dose-dependent manner. Low doses of nanoparticles have shown possibilities to induce moderate ROS increases and lead to adaptive responses of biological systems, but benef...
Gespeichert in:
Veröffentlicht in: | Nature communications 2023-06, Vol.14 (1), p.3643-3643, Article 3643 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Accumulation of inorganic nanoparticles in living organisms can cause an increase in cellular reactive oxygen species (ROS) in a dose-dependent manner. Low doses of nanoparticles have shown possibilities to induce moderate ROS increases and lead to adaptive responses of biological systems, but beneficial effects of such responses on metabolic health remain elusive. Here, we report that repeated oral administrations of various inorganic nanoparticles, including TiO
2
, Au, and NaYF
4
nanoparticles at low doses, can promote lipid degradation and alleviate steatosis in the liver of male mice. We show that low-level uptake of nanoparticles evokes an unusual antioxidant response in hepatocytes by promoting
Ces2h
expression and consequently enhancing ester hydrolysis. This process can be implemented to treat specific hepatic metabolic disorders, such as fatty liver in both genetic and high-fat-diet obese mice without causing observed adverse effects. Our results demonstrate that low-dose nanoparticle administration may serve as a promising treatment for metabolic regulation.
Inorganic nanoparticles can accumulate in living organisms causing a dose-dependent increase in cellular reactive oxygen species. Here, the authors leverage this as a potential scheme for regulating metabolic disorders, showing that that low-dose nanoparticle administration can enhance lipid hydrolysis and alleviate fatty liver. |
---|---|
ISSN: | 2041-1723 2041-1723 |
DOI: | 10.1038/s41467-023-39423-3 |